Inhibrx Reports Second Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program
How this was made
The 30-second read
Why it matters
Key new items are (1) an Oxford loan amendment adding $325M gross proceeds with $100M funded at execution and up to $225M available in future increments, (2) FDA acceptance for filing of the ozekibart BLA with a PDUFA goal date of April 14, 2027, and (3) planned clinical data timing for INBRX-106 (PFS data in Q3 2026) and ozekibart Phase 1 cohort interim results (expected Q1 2027).
Market read
The filing is actionable for INBX traders because it combines liquidity expansion with a concrete FDA milestone date, while also mapping the next clinical catalysts into 2026-2027.
What to watch
The article provides cash and expense deltas but no updated guidance on total runway length or dilution plans; traders should monitor whether Oxford funding is likely to be drawn and at what cost.
Background
This is an SEC 8-K (Item 2.02) with an exhibit summarizing Inhibrx’s Q2 2026 financial results and key corporate/regulatory milestones.
Ticker impact
Inhibrx disclosed a second Oxford loan amendment adding up to $225M, plus Q2 cash jump to $219.5M and updated BLA/PDUFA timing.
Bias to upside or reduced downside risk, with follow-through likely into the next data and FDA milestone windows (Q3 2026 PFS data, Q1 2027 interim cohorts, and April 14, 2027 PDUFA).
The filing is a primary disclosure (8-K with exhibit) that increases liquidity via incremental loan proceeds and confirms FDA acceptance with a specific PDUFA goal date, both of which can re-rate financing and regulatory timelines.
Market effects
Supports sentiment for clinical-stage biopharma financing and FDA-regulatory progress narratives, especially for oncology programs.
Primarily US-focused via FDA actions and Nasdaq-listed issuer; limited direct regional spillover.
Modest global relevance, as the catalysts are FDA-specific and company-specific rather than platform-wide.
Counterpoint
Loan amendments can extend runway but also signal ongoing capital needs; equity may still face dilution risk if trial and manufacturing spend accelerates.
Key entities
- issuerInhibrx Biosciences, Inc.
Clinical-stage biopharmaceutical company reporting Q2 2026 results and financing/regulatory milestones.
- lenderOxford Finance LLC
Counterparty to the amended Loan and Security Agreement providing incremental gross proceeds.
- regulatorU.S. Food and Drug Administration (FDA)
Accepted the ozekibart BLA for filing and set a PDUFA goal date of April 14, 2027.
- drug_programINBRX-109 (ozekibart)
Oncology candidate with BLA acceptance for conventional chondrosarcoma and planned regulatory discussions for CRC.
- drug_programINBRX-106
Phase 2 HNSCC program planned to report PFS data in combination with pembrolizumab in Q3 2026.
